About
Acumen Pharmaceuticals
ABOS.US
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc.
Profile
- Company Name
- Acumen Pharmaceuticals, Inc.
- Market
- NasdaqGS
- Founded
- Industry
- --
- Fiscal Year End
- December 31
- Website
- acumenpharm.com